"Shouldn't Overreact To Delays In Covaxin Approval": Biocon's Kiran Shaw To NDTV
"This (approval of Covaxin) is excellent news. WHO follows stringent guidelines - a lot of data points need to be submitted. We should not overreact to the delay in its approval," says Biocon's Executive Chairperson Kiran Mazumdar Shaw.
